Last reviewed · How we verify
Intravenous oxytocin infusion
Oxytocin is a neurohypophyseal hormone that binds to oxytocin receptors to stimulate uterine contractions and promote milk letdown during lactation.
Oxytocin is a neurohypophyseal hormone that binds to oxytocin receptors to stimulate uterine contractions and promote milk letdown during lactation. Used for Labor induction, Labor augmentation, Prevention and treatment of postpartum hemorrhage.
At a glance
| Generic name | Intravenous oxytocin infusion |
|---|---|
| Sponsor | Tel-Aviv Sourasky Medical Center |
| Drug class | Neurohypophyseal hormone |
| Target | Oxytocin receptor (OXTR) |
| Modality | Small molecule |
| Therapeutic area | Obstetrics |
| Phase | Phase 3 |
Mechanism of action
Oxytocin acts as both a hormone and neurotransmitter, binding to G-protein coupled oxytocin receptors on uterine smooth muscle cells to trigger rhythmic contractions. In obstetrics, intravenous infusion is used to induce or augment labor by increasing the frequency and strength of uterine contractions. The hormone also facilitates milk ejection during breastfeeding by contracting myoepithelial cells in mammary glands.
Approved indications
- Labor induction
- Labor augmentation
- Prevention and treatment of postpartum hemorrhage
Common side effects
- Uterine hyperstimulation
- Fetal heart rate abnormalities
- Nausea and vomiting
- Headache
- Water intoxication (at high doses)
- Hypertension
Key clinical trials
- The Stimulation To Induce Mothers Study (PHASE4)
- Effects Of Intravenous Oxytocin On Peripheral Sensory Afferents Using Microneurography (PHASE2)
- Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain (PHASE2)
- A Randomized Controlled Trial to Test the Effects Oxytocin and Vibration Have on Heat Pain Threshold After UV-B Burn (PHASE2)
- Intravenous Oxytocin for Post Operative Pain After Minimally Invasive Hysterectomy (PHASE2)
- Defining a PK and PD Model for Peripheral Analgesia After IV Oxytocin (PHASE2)
- Rectal Misoprostol for Reducing Blood Loss in Elective Cesarean Section (NA)
- A Study of Oxytocin PK After IV Administration in Healthy Subjects and Advanced Knee Arthritis Subjects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous oxytocin infusion CI brief — competitive landscape report
- Intravenous oxytocin infusion updates RSS · CI watch RSS
- Tel-Aviv Sourasky Medical Center portfolio CI